Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
Neurology Advisor Articles
- Self-Controlled Electric Stimulation a Good Alternative to Drug Therapy for Migraine
- Elevated Copeptin Levels in Acute Headache May Signify More Serious Etiology
- New Sleep Apnea Clinical Practice Guidelines
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- Neural Targeting Spinal Cord Stimulation Superior for Axial Low Back Pain
- DHA Supplementation Has No Impact on IQ in Offspring
- Safinamide Approved as Adjunctive Therapy for Parkinson's
- International League Against Epilepsy Updates Epilepsy Classification System
- Depression, Schizophrenia Identified With Objective Blood Biomarker
- Autoimmune Disease Hospitalization Linked to Future Dementia Risk